Ok so Corvus did a secondary and better yet the CEO bought in. Two positives! BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offering were sold by Corvus, with gross proceeds to Corvus of $34.2 million and net proceeds of approximately $31.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are acting as joint book-running managers for the offering. --> Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19 Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure This was the thought before the capital raise... Summary Corvus is a small biotech targeting the adenosine cancer pathway with two assets in clinical development, with a credible path to approval for its A2A Receptor Antagonist. The company is prioritizing development of its CD73 candidate, CPI-006 as a COVID-19 treatment and hopes to initiate a pivotal Phase 3 trial this year based on solid data. Shares trade at $3.7 and Corvus' market cap is just $104m, despite its diversified portfolio of assets. An experienced management team adds weight to the thesis that the company may be significantly undervalued. With little cash, a development partner would be welcome. Now They Have a little cash.... Corvus CRVS Is A Gumy Of The Day-!
Yes ELYS has the cheapo machines I see they have had a big 2 days but it has been a dog. Was $6.30 a month ago. In that time, it seems most of these stocks have doubled and tripled. A guy at Churchill Downs told me the machines are garbage. I still do not like.-
Oh my word: IMNM- IMNM 302 followersImmunome, Inc. 22.22 -1.66(-6.95%) 3:58 PM 02/17/21 Pre-Market:$56.56+34.34(+154.54%)7:49 AM- WTF WHY IS IT NEVER ME!!!!!!!
Hey this FRX SPAC might be one to do a quick flip on. They're buying BeachBody lol. https://www.teambeachbody.com/shop/us/corporate/aboutus It's $11.80 Momentum buyers from Robinhood starting to hit it. It'll drop though. Wait for low $11's Unless the volume picks up.
This is our girl? Biography Born in Orenburg. She graduated from Vaganova Academy of Russian Ballet, St. Petersburg, Lyudmila Sofronova’s class, in 2009, and joined the Mariinsky Ballet Company the same year. When did she start with the Track and Field?
Absolutely ZERO Debt. 8M shares in the float, and $10M cash on the books. With Guido buying his own stock like it was mama-La-Belles meatballs. So a double since early December is a dog? Who'd you talk to out at Churchill downs. Its closed. The guy that cleans the stables?
What Is The Butterfly Network? Cool name. One new option listing and one option delisting on February 16th 08:30 BFLY, LGVW New option listings for February 16th include Butterfly Network Inc (Class A Stock) (BFLY). Option delistings effective February 16th include Longview Acquisition Corp (Class A Stock) (LGVW). Options just made available and stock ismoving. May have been a SPAC-- Longview Acquisition Corp. (LGVW) up 8% after Butterfly Network and the company announced that they have entered into a definitive business combination agreement. with the pro forma enterprise value of the merger being $1.5B Butterfly Network Inc (Class A Stock) call volume above normal and directionally bullish 15:45 BFLY Bullish option flow detected in Butterfly Network Inc (Class A Stock) with 33,502 calls trading, 5x expected, and implied vol increasing almost 9 points to 137.81%. Feb-21 25 calls and Feb-21 20 calls are the most active options, with total volume in those strikes near 11,800 contracts. The Put/Call Ratio is 0.08. Butterfly Network, a Global Leader in Democratizing Medical Imaging, Closes Business Combination and Will Begin Trading on the New York Stock Exchange -- Announces unaudited 2020 full-year revenue of at least $45 million, representing growth of at least 63%, each above prior forecast---